| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8441880 | European Journal of Cancer | 2015 | 11 Pages |
Abstract
Combinations of cixutumumab or ramucirumab plus MP were feasible and associated with moderate toxicities in docetaxel-pretreated men with mCRPC. Of the two regimens, the ramucirumab regimen is worthy of further testing based on the observed cPFS relative to the historical control.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Maha Hussain, Dana Rathkopf, Glenn Liu, Andrew Armstrong, Wm. Kevin Kelly, Anna Ferrari, John Hainsworth, Adarsh Joshi, Rebecca R. Hozak, Ling Yang, Jonathan D. Schwartz, Celestia S. Higano,